An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Cancer treatment communications Pub Date : 2015-01-01 DOI:10.1016/j.ctrc.2015.11.003

Jianqing Lin , Aileen Deng , Jean Hoffman-Censits , Geoffrey Gibney , Terry Hyslop , Brooke Miller , Deborah Kilpatrick , Serge Jabbour , William Kevin Kelly

{"title":"An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients","authors":"Jianqing Lin , Aileen Deng , Jean Hoffman-Censits , Geoffrey Gibney , Terry Hyslop , Brooke Miller , Deborah Kilpatrick , Serge Jabbour , William Kevin Kelly","doi":"10.1016/j.ctrc.2015.11.003","DOIUrl":null,"url":null,"abstract":"<div><p>New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.11.003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221308961530027X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

一项开放标签随机II期研究，pasireotide联合或不联合依维莫司治疗去势抵抗chemotherapy-naïve前列腺癌患者

新的研究领域继续研究非雄激素受体途径在前列腺癌治疗中的作用。磷脂酰肌醇3-激酶/Akt/哺乳动物雷帕霉素靶蛋白(mTOR)通路可能是前列腺癌治疗的靶点。生长抑素受体信号抑制细胞内PI3K/Akt信号，使其成为联合治疗的一个有吸引力的靶点。我们进行了一项II期开放标签临床试验，检查生长抑素受体激动剂pasireotide (SOM230)与mTOR抑制剂依维莫司联合用于转移性阉割抵抗chemotherapy-naïve前列腺癌患者。在参与研究的6名患者中，只有1名患者的PSA较基线降低了50%。3例患者因3级不良事件退出治疗。由于毒性分析，该研究提前结束，并且没有计划进一步开发这种联合治疗前列腺癌的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer treatment communications

自引率

0.00%

发文量